BeiGene to Present at Upcoming Investor Conferences
28 Febbraio 2024 - 2:05PM
Business Wire
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global
oncology company, today announced that the Company will participate
in fireside chats at two upcoming investor conferences:
- TD Cowen 44th Annual Health Care Conference on Tuesday, March
5th, 2024 at 9:50 am ET; and
- Leerink Partners Global Biopharma Conference on Monday, March
11th, 2024 at 10:00 am ET
Live webcasts of these events can be accessed from the investors
section of BeiGene’s website at http://ir.beigene.com,
https://hkexir.beigene.com/, https://sseir.beigene.com/. Archived
replays will be available for 90 days following the event.
About BeiGene
BeiGene is a global oncology company that is discovering and
developing innovative treatments that are more accessible and
affordable to cancer patients worldwide. With a broad portfolio, we
are expediting development of our diverse pipeline of novel
therapeutics through our internal capabilities and collaborations.
We are committed to radically improving access to medicines for far
more patients who need them. Our growing global team of more than
10,000 colleagues spans five continents, with administrative
offices in Basel; Beijing; and Cambridge, U.S. To learn more about
BeiGene, please visit www.beigene.com and follow us on LinkedIn and
X (formerly known as Twitter) at @BeiGeneGlobal.
Forward-Looking Statements
This presentation may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
BeiGene's plans, commitments, aspirations and goals related to
BeiGene’s medicines and drug candidates. Actual results may differ
materially from those indicated in the forward-looking statements
as a result of various important factors which are discussed in the
section entitled “Risk Factors” in BeiGene’s most recent annual
report on Form 10-K filed with the U.S. Securities and Exchange
Commission (“SEC”) as well as discussions of potential risks,
uncertainties, and other important factors in BeiGene's subsequent
filings with the SEC. All information in this presentation is as of
the date presented, and BeiGene undertakes no duty to update such
information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240228354635/en/
Investors: Liza Heapes +1 857-302-5663 ir@beigene.com
Media: Kyle Blankenship +1 667-351-5176
media@beigene.com
Grafico Azioni BeiGene (NASDAQ:BGNE)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni BeiGene (NASDAQ:BGNE)
Storico
Da Mag 2023 a Mag 2024